Actionable Evidence Fuels Genetic Disease Recognition and
Scientific Progress
ANN
ARBOR, Mich., July 11,
2024 /PRNewswire-PRWeb/ -- Genomenon, a leader in
genomic intelligence, today announced the launch of its Genetic
Disease Sponsorship program. This groundbreaking initiative aims to
raise awareness, facilitate earlier diagnosis, and drive scientific
advancements for genetic diseases.
"Our Genetic Disease Sponsorship programs
provide easy access to critical evidence that enables faster, more
accurate interpretation of genetic tests, thus promoting disease
awareness and increased diagnostic rates." - Dr. Mark Kiel, CSO and co-founder of Genomenon
Through this program, Genomenon offers its extensive network of
over 2,000 clinical laboratories in more than 140 countries
exclusive access to genetic variants specific to a sponsor's
disease of interest. This network accelerates the diagnostic
process, benefiting patients and advancing scientific
knowledge.
"Early and accurate diagnosis is crucial for individuals living
with genetic diseases," said Dr. Mark
Kiel, CSO and co-founder of Genomenon. "Our Genetic Disease
Sponsorship programs provide easy access to critical evidence that
enables faster, more accurate interpretation of genetic tests, thus
promoting disease awareness and increased diagnostic rates."
Early partners in Genomenon's beta program are passionate about
the Genetic Disease Sponsorship's mission:
"Pharming's dedication to serving patients with rare diseases is
the driving force behind forming partnerships with companies such
as Genomenon," said Heather
McLaughlin, Senior Director of Molecular Diagnostics at
Pharming. "By providing laboratories and clinicians with
comprehensive and clear variant interpretation data, we help ensure
patients with APDS receive earlier, more accurate diagnoses and
appropriate medical management. Pharming is unwavering in its
commitment to rare disease patient populations and supporting the
caregivers and doctors who serve these patients daily."
Using its Mastermind Genomic Intelligence Platform, Genomenon
delivers a locus-specific database that identifies the most
comprehensive set of causative variants for a specific disease.
These rich genomic data—known as variant landscapes—complement
Pharming's efforts by enhancing the accessibility and understanding
of the genetic underpinnings of APDS.
Key benefits of the Genetic Disease Sponsorship include:
- Expanded Awareness of Disease: Participation helps raise
awareness about specific genetic diseases, leading to better -
understanding, earlier diagnosis, and improved patient
outcomes.
- Promoting Increased Diagnosis: The sponsorship facilitates the
diagnosis of genetic diseases by providing access to genomic data
and an established clinical network, increasing the chances of
accurately diagnosing rare or complex conditions.
- Immediate Access to an Established Clinical Network:
Participants gain access to a vast network of over 2,000 clinical
labs in 140 countries worldwide.
- Contribution to the Scientific Community: Sharing genomic data
and insights advances scientific research. Organizations contribute
to the collective knowledge about genetic diseases, potentially
leading to breakthroughs in treatment and prevention.
Genomenon is committed to advancing healthcare and improving
lives by making genomic information actionable. The Genetic Disease
Sponsorship program exemplifies this mission by fostering
collaboration, raising awareness, and driving scientific
progress.
More information on Genomenon and the Genetic Disease
Sponsorship program, may be found here.
Media Contact:
Colleen McMillen
cmcmillen@genomenon.com
About Genomenon
Genomenon is a genomics intelligence company dedicated to improving
the quality of life of genetic disease and cancer patients by
making genomic information actionable. Blending the power of AI
with the precision of genomic expertise, the company empowers
pharmaceutical companies and the clinical diagnostic community with
empirical genomic evidence and insights that both support the
development of novel therapeutics and speed diagnostic assessments
and treatment recommendations.
Media Contact
Colleen McMillen,
https://www.genomenon.com, 9173449360, cmcmillen@genomenon.com,
https://www.genomenon.com
Twitter
View original
content:https://www.prweb.com/releases/genomenon-launches-genetic-disease-sponsorship-to-boost-rare-disease-diagnosis-302194408.html
SOURCE Genomenon